Cullinan Oncology to Participate in Upcoming Investor Conferences
Cullinan Therapeutics, Inc. (CGEM)
NASDAQ:AMEX Investor Relations:
investorshub.advfn.com/consolidated-gems-inc-cgem-26232
Company Research
Source: GlobeNewswire
CAMBRIDGE, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan Oncology”) a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today announced its participation in the following upcoming investor conferences: Jeffrey Jones, M.D., M.P.H., M.B.A., Chief Medical Officer, will participate in a Panel Discussion on Gynecologic Cancers at the TD Cowen 44th Annual Health Care Conference in Boston, MA on Tuesday, March 5, 2024, at 10:30 AM ET.Jeff Trigilio, Chief Financial Officer, will participate in a fireside chat at the Leerink Partners Global Biopharma Conference in Miami, FL on Wednesday, March 13, 2024, at 8:00 AM ET. A webcast of the TD Cowen panel discussion will be available under the Events and Presentations section of the Company’s Investor Relations website at https://cullinanoncology.com/events-and-presentations/. About Cullinan Oncology Cullinan Oncology, Inc. (Nasdaq: CGEM) is a biopharmaceutical com
Show less
Read more
Impact Snapshot
Event Time:
CGEM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CGEM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CGEM alerts
High impacting Cullinan Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CGEM
News
- Why Is Cullinan Therapeutics Stock Trading Higher On Wednesday? [Yahoo! Finance]Yahoo! Finance
- Cullinan Therapeutics to Present Clinical Data from Phase 1 Study Evaluating Novel Anti-MICA/B Antibody, CLN-619, as Monotherapy and in Combination with a Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ASCO 2024GlobeNewswire
- EGFR Inhibitor Market to Accelerate Substantially During the Study Period (2020–2034) | DelveInsight [Yahoo! Finance]Yahoo! Finance
- Cullinan Oncology, Inc. (NASDAQ: CGEM) had its price target raised by analysts at Jonestrading from $22.00 to $26.00. They now have a "buy" rating on the stock.MarketBeat
- Cullinan Oncology, Inc. (NASDAQ: CGEM) had its price target lowered by analysts at HC Wainwright from $34.00 to $29.00. They now have a "buy" rating on the stock.MarketBeat
CGEM
Earnings
- 3/14/24 - Beat
CGEM
Sec Filings
- 4/24/24 - Form SC
- 4/16/24 - Form 8-K
- 4/2/24 - Form 3
- CGEM's page on the SEC website